NovAccess Global Inc.: directors' dealings · United States · SEC (Form 4)

About NovAccess Global Inc.

NovAccess Global Inc. is a U.S.-based biopharmaceutical company with a highly specialized profile in brain-cancer immunotherapy. In the public sources reviewed, the company is not described as a NYSE or NASDAQ issuer; rather, it is presented as a microcap health-care name followed through SEC filings and insider-transaction activity. For investors, that matters: NovAccess should be assessed as an early-stage, development-focused company rather than as a commercial-stage pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1039466/000118518526000158/novaccess10k093024.htm)) The company’s core business is the development of novel immunotherapies for brain tumor patients in the United States, with plans to expand globally. Its 10-K states that NovAccess is working on an Investigational New Drug application and is engaging with the FDA to obtain permission for human clinical trials. The scientific thesis is centered on using a patient’s own immune system to attack cancer, which places the company in the broader oncology-immunotherapy landscape, but with a very narrow and clinically challenging focus on brain tumors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1039466/000118518526000158/novaccess10k093024.htm)) A key milestone in the company’s recent history was the September 2020 acquisition of StemVax, LLC. Through that transaction, NovAccess gained an exclusive patent license from Cedars-Sinai Medical Center in Los Angeles for StemVax Glioblast (SVX-GB/TLR-AD1), a program aimed at glioblastoma, the most common and among the deadliest adult brain tumors. This acquisition is important strategically because it gave NovAccess a more defined intellectual-property and product-development platform around which to build its pipeline narrative. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1039466/000118518526000158/novaccess10k093024.htm)) From a competitive standpoint, NovAccess operates in a crowded and capital-intensive field dominated by larger biotech and pharma groups with deeper funding, broader pipelines, and more advanced clinical infrastructure. NovAccess’s differentiation appears to come from its focused scientific approach, its licensed IP, and its positioning in a high-unmet-need indication. At the same time, the company’s disclosure history suggests a continuing reliance on external financing and short-term borrowing arrangements, highlighting the balance-sheet and execution risk that typically accompanies preclinical or IND-stage biotech names. ([novaccessglobal.com](https://novaccessglobal.com/wp-content/uploads/2024/03/3_1_24-NovAccess-Global-Provides-Business-Updates-and-Announces-Scheduling-of-Annual-Meeting-of-Shareholders.pdf)) Geographically, the company is headquartered in Cleveland, Ohio, United States, while its stated development ambitions extend beyond the domestic market. Recent corporate updates indicate that in March 2024 NovAccess disclosed that its fiscal 2023 annual report had been filed, that first-quarter fiscal 2024 results had been reported, and that it was preparing for its annual shareholder meeting. The same update referenced management participation in a neuroscience-focused congress in Los Angeles, underscoring the company’s emphasis on brain mapping, neurotechnology, and therapeutic innovation. Overall, NovAccess Global remains a speculative but scientifically targeted small-cap biotech story, with upside tied to regulatory progress and clinical validation rather than near-term revenue generation. ([novaccessglobal.com](https://novaccessglobal.com/wp-content/uploads/2024/03/3_1_24-NovAccess-Global-Provides-Business-Updates-and-Announces-Scheduling-of-Annual-Meeting-of-Shareholders.pdf))